Ipca Labs, Cadila Health 'could be at risk' as USFDA cautions on use of hydroxychloroquine
Updated : April 27, 2020 03:08 PM IST
The USFDA stated that HCQS use should be limited to clinical trials or treating certain hospitalized patients.
Ipca Labs and Cadila Healthcare fell up to 5 percent on Monday post this development.
Ipca Labs and Cadila Healthcare have risen over 40 percent and 30 percent, respectively in 2020.